Value of Child-Turcotte-Pugh Score in Prediction of Treatment Response in “Difficult to Treat” Chronic HCV Cirrhotic Patients — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Value of Child-Turcotte-Pugh Score in Prediction of Treatment Response in “Difficult to Treat” Chronic HCV Cirrhotic Patients
Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
,
Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
,
Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3 Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Background and aim: The direct-acting antivirals (DAAs) treatment has greatly improved sustained virologic response (SVR) in chronic non-cirrhotic hepatitis C virus (HCV) patients and to less extent in those with cirrhosis. There is a stressing need for predicting the outcome of DAAs treatment especially in “difficult to treat” patients. This work aimed to study the value of the Child-Turcotte-Pugh (CTP) score in the prediction of treatment outcome with DAAs in “difficult to treat” chronic HCV patients. Materials and methods: A retrospective cohort study was conducted where files of 120 “difficult to treat” patients were randomly selected from the follow-up clinic. Patients’ data were collected before and after treatment including history taking, clinical examination, laboratory investigations, and abdominal ultrasonography. Child-Turcotte-Pugh (CTP) scores were calculated. Results: There was no significant difference in mean Child score between patients with and without SVR before treatment, while this difference became significant after treatment. The patients without complications showed a highly significant decrease in their mean Child score after treatment, while patients with complications did not show any significant differences. Conclusion: The baseline Child-Turcotte-Pugh score cannot predict the treatment response of DAAs in “difficult to treat” chronic HCV patients, but it is significantly associated with the occurrence of complications.
KeywordsHepatitis CChild ScoreCirrhosis
WHO (2014) Hepatitis C: Fact Sheet N 164.
Davis, G.L., Albright, J.E., Cook, S.F. and Rosenberg, D.M. (2003) Projecting Future Complications of Chronic Hepatitis C in the United States. Liver Transplantation, 9, 331-338. https://doi.org/10.1053/jlts.2003.50073
El-Serag, H.B. and Mason, A.C. (1999) Rising Incidence of Hepatocellular Carcinoma in the United States. The New England Journal of Medicine, 340, 745-750. https://doi.org/10.1056/NEJM199903113401001
Verna, E.C. and Brown Jr., R.S. (2006) Hepatitis C Virus and Liver Transplantation. Clinical Liver Disease, 10, 919-940. https://doi.org/10.1016/j.cld.2006.08.012
Velosa, J., Serejo, F., Marinho, R., Nunes, J. and Glória, H. (2011) Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis. Digestive Diseases and Sciences, 56, 1853-1861. https://doi.org/10.1007/s10620-011-1621-2
Van der Meer, A.J., Wedemeyer, H., Feld, J.J., Dufour, J.F., Zeuzem, S., Hansen, B.E. and Janssen, H.L. (2014) Life Expectancy in Patients with Chronic HCV Infection and Cirrhosis Compared with a General Population. JAMA, 312, 1927-1928. https://doi.org/10.1001/jama.2014.12627
Hsu, C.S., Chao, Y.C., Lin, H.H., Chen, D.S. and Kao, J.H. (2015) Systematic Review: Impact of Interferon-Based Therapy on HCV-Related Hepatocellular Carcinoma. Scientific Reports, 5, Article No. 9954. https://doi.org/10.1038/srep09954
Welzel, T.M., Dultz, G. and Zeuzem, S. (2014) Interferon-Free Antiviral Combination Therapies without Nucleosidic Polymerase Inhibitors. Journal of Hepatology, 61, S98-S107. https://doi.org/10.1016/j.jhep.2014.08.014
Han, D.S., Hahm, B., Rho, H.M. and Jang, S.K. (1995) Identification of the Protease Domain in NS3 of Hepatitis C Virus. Journal of General Virology, 76, 985-993. https://doi.org/10.1099/0022-1317-76-4-985
Foster, G.R., Irving, W.L., Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., Brown, A., Gelson, W.T., et al. (2016) Impact of Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C and Decompensated Cirrhosis. Journal of Hepatology, 64, 1224-1231. https://doi.org/10.1016/j.jhep.2016.01.029
Steinebrunner, N., Stein, K., Sandig, C., Bruckner, T., Stremmel, W. and Pathil, A. (2018) Predictors of Functional Benefit of Hepatitis C Therapy in a “Real-Life” Cohort. World Journal of Gastroenterology, 24, 852-861. https://doi.org/10.3748/wjg.v24.i7.852
Cavalcante, L.N. and Lyra, A.C. (2015) Predictive Factors Associated with Hepatitis C Antiviral Therapy Response. World Journal of Hepatology, 7, 1617-1631. https://doi.org/10.4254/wjh.v7.i12.1617
Afdhal, N.H., McHutchison, J.G., Zeuzem, S., et al. (2011) Hepatitis C Pharmacogenetics: State of the Art in 2010. Hepatology, 53, 336-345. https://doi.org/10.1002/hep.24052
Hadziyannis, S.J., Sette, H., Morgan, T.R., et al. (2004) Peginterferon Alpha 2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose. Annals of Internal Medicine, 140, 346-355. https://doi.org/10.7326/0003-4819-140-5-200403020-00010
Manns, M.P., Wedemeyer, H. and Cornberg, M. (2006) Treating Viral Hepatitis C: Efficacy, Side Effects, and Complications. Gut, 55, 1350-1359. https://doi.org/10.1136/gut.2005.076646
Ahmed, O.A., Elsebaey, M.A., Fouad, M.H.A., Elashry, H., Elshafie, A.I., Elhadidy, A.A., Esheba, N.E., Elnaggar, M.H., Soliman, S. and Abd-Elsalam, S. (2018) Outcomes and Predictors of Treatment Response with Sofosbuvir plus Daclatasvir with or without Ribavirin in Egyptian Patients with Genotype 4 Hepatitis C Virus Infection. Infection and Drug Resistance, 11, 441-445. https://doi.org/10.2147/IDR.S160593
Cholongitas, E., Papatheodoridis, G.V., Vangeli, M., Terreni, N., Patch, D. and Burroughs, A.K. (2005) Systematic Review: The Model for End-Stage Liver Disease—Should It Replace Child-Pugh’s Classification for Assessing Prognosis in Cirrhosis? Alimentary Pharmacology & Therapeutics, 22, 1079-1089. https://doi.org/10.1111/j.1365-2036.2005.02691.x
Saxena, V., Nyberg, L., Pauly, M., Dasgupta, A., Nyberg, A., Piasecki, B., Winston, B., Redd, J., Ready, J. and Terrault, N. (2015) Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C Infected Patients with Compensated and Decompensated Cirrhosis. Hepatology, 62, 715-725. https://doi.org/10.1002/hep.27922
El-Akel, W., El-Sayed, M.H., El Kassas, M., et al. (2017) National Treatment Programme of Hepatitis C in Egypt: Hepatitis C Virus Model of Care. Journal of Viral Hepatitis, 24, 262-267. https://doi.org/10.1111/jvh.12668
Ahmed, O.A., Kaisar, H.H., Hawash, N., et al. (2017) Efficacy of Sofosbuvir plus Ribavirin with or without Peginterferon-Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection. Infectious Disorders Drug Targets, 17, 95-100. https://doi.org/10.2174/1871526517666170417143216
AbdElrazek, A.E., Bilasy, S.E., Elbanna, A.E., et al. (2014) Prior to the Oral Therapy, What Do We Know about HCV-4 in Egypt: A Randomized Survey of Prevalence and Risks Using Data Mining Computed Analysis. Medicine (Baltimore), 93, e204. https://doi.org/10.1097/MD.0000000000000204
Pol, S., Corouge, M. and vallet-Pichard, A. (2016) Daclatas-vir-Sofosbuvir Combination Therapy with or without Ribavirin for Hepatitis C Virus Infection: From the Clinical Trials to Real Life. Hepatic Medicine, 8, 21-26. https://doi.org/10.2147/HMER.S62014
Carrion, A.F., Khaderi, S.A. and Sussman, N.L. (2016) Model for End-Stage Liver Disease Limbo, Model for End-Stage Liver Disease Purgatory, and the Dilemma of Treating Hepatitis C in Patients Awaiting Liver Transplantation. Liver Transplantation, 22, 279-280. https://doi.org/10.1002/lt.24383
El-Sherif, El-Raziky, El-Akel, W., et al. (2018) Planning and Prioritizing Direct-Acting Antivirals Treatment for HCV Patients in Countries with Limited Resources: Lessons from the Egyptian Experience. Journal of Hepatology, 23, 235-244.
Omar, H., Elakel, W., Elbaz, T., et al. (2017) Generic Daclatasvir plus Sofosbuvir, with or without Ribavirin, in Treatment of Chronic Hepatitis C: Real-World Results from 18 378 Patients in Egypt. Alimentary Pharmacology & Therapeutics, 1, 11-47. https://doi.org/10.1111/apt.14428
Wahsh, E.A., Hussein, A.K., Gomaa, A.A., et al. (2018) Real Life Egyptian Experience of Daclatasvir plus Sofosbuvir with Ribavirin in Naive Difficult to Treat HCV Patients. Infectious Disorders Drug Targets, 18, 1.
Ahmed, O.A., Elsebaey, M.A., Fouad, M.H., et al. (2018) Outcomes and Predictors of Treatment Response with Sofosbuvir plus Daclatasvir with or without Ribavirin in Egyptian Patients with Genotype 4 Hepatitis C Virus Infection. Infection and Drug Resistance, 11, 441-445. https://doi.org/10.2147/IDR.S160593
Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. (2014) Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. The New England Journal of Medicine, 370, 211-221. https://doi.org/10.1056/NEJMx140011
Carrillo, C.F., Lens, S., Llop, E., et al. (2017) Treatment of Hepatitis C Virus Infection in Patients with Cirrhosis and Predictive Value of MELD: Analysis of Data from the Hepa-C Registry. Hepatology, 65, 1810-1822. https://doi.org/10.1002/hep.29097
Deterding, K., Honer, Z.U., Siederdissen, C., et al. (2015) Improvement of Liver Function Parameters in Advanced HCV-Associated Liver Cirrhosis by IFN-Free Antiviral Therapies. Alimentary Pharmacology & Therapeutics, 42, 889-901. https://doi.org/10.1111/apt.13343
Mehta, K.M., Nandwani, B., et al. (2017) Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major. Journal of Clinical and Experimental Hepatology, 8, 1564-1566. https://doi.org/10.1016/j.jceh.2017.06.002
Charlton, M., Gane, E., Manns, M.P., et al. (2015) Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection after Liver Transplantation. Gastroenterology, 148, 108-117. https://doi.org/10.1053/j.gastro.2014.10.001
Manns, M., Samuel, D., Gane, E.J., et al. (2016) Ledipasvir and Sofosbuvir plus Ribavirin in Patients with Genotype 1 or 4 Hepatitis C Virus Infection and Advanced Liver Disease: A Multicentre, Open-Label, Randomized, Phase 2 Trial. The Lancet Infectious Diseases, 16, 685-697. https://doi.org/10.1016/S1473-3099(16)00052-9
Van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. (2014) Association between Sustained Virological Response and All-Cause Mortality among Patients with Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA, 308, 2584-2593. https://doi.org/10.1001/jama.2012.144878